MCID: BNG030
MIFTS: 60

Benign Ependymoma

Categories: Cancer diseases, Neuronal diseases

Aliases & Classifications for Benign Ependymoma

MalaCards integrated aliases for Benign Ependymoma:

Name: Benign Ependymoma 12 15
Ependymoma 43 17 71
Who Grade Ii Ependymal Tumor 12
Myxopapillary Ependymoma 71
Epithelial Ependymoma 12

Classifications:



Summaries for Benign Ependymoma

MalaCards based summary : Benign Ependymoma, also known as ependymoma, is related to tanycytic ependymoma and malignant ependymoma, and has symptoms including back pain An important gene associated with Benign Ependymoma is MEN1 (Menin 1), and among its related pathways/superpathways are ERK Signaling and PI3K-Akt signaling pathway. The drugs Temozolomide and Carboplatin have been mentioned in the context of this disorder. Affiliated tissues include brain, spinal cord and pituitary, and related phenotypes are ependymoma and migraine

Wikipedia : 74 An ependymoma is a tumor that arises from the ependyma, a tissue of the central nervous system. Usually,... more...

Related Diseases for Benign Ependymoma

Diseases in the Benign Ependymoma family:

Malignant Ependymoma Malignant Adult Ependymoma

Diseases related to Benign Ependymoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 641)
# Related Disease Score Top Affiliating Genes
1 tanycytic ependymoma 34.3 SYP NF2 GFAP
2 malignant ependymoma 34.1 NF2 MGMT GFAP EGFR
3 anaplastic ependymoma 33.9 VIM SYP NF2 MUC1 MDM2 GFAP
4 papillary ependymoma 33.8 TTR SYP GFAP ENO2
5 clear cell ependymoma 33.7 VIM SYP MUC1 GFAP ENO2
6 subependymoma 32.6 TSC2 SYP NES GFAP ENO2
7 glioma 32.5 PDGFRA NF1 MDM2 HOTAIR EGFR
8 multiple endocrine neoplasia, type i 32.4 SYP NF1 MEN1 CDKN2B
9 glioma susceptibility 1 31.6 PDGFRA NES MTOR MGMT MDM2 HOTAIR
10 subependymal glioma 31.6 TSC2 TSC1 NF1 MTOR
11 secretory meningioma 31.5 VIM NF2 MUC1
12 meningioma, radiation-induced 31.3 VIM NF2 MUC1 GFAP
13 angiocentric glioma 30.9 VIM SYP GFAP
14 central neurocytoma 30.9 SYP NES GFAP ENO2
15 teratoma 30.8 VIM SYP NES GFAP ENO2
16 juvenile pilocytic astrocytoma 30.7 SYP NF1 NES MGMT GFAP
17 ependymoblastoma 30.7 VIM SYP NES GFAP ENO2
18 oligoastrocytoma 30.7 MGMT GFAP
19 hydrocephalus 30.7 VIM TTR SYP NES GFAP ENO2
20 acoustic neuroma 30.7 NF2 NF1 MGMT
21 pleomorphic xanthoastrocytoma 30.6 SYP MGMT GFAP
22 mucinous adenocarcinoma 30.6 VIM MUC1 EGFR
23 cystic teratoma 30.6 SYP GFAP ENO2
24 cauda equina neoplasm 30.6 SYP ENO2
25 pineocytoma 30.5 SYP GFAP ENO2
26 supratentorial primitive neuroectodermal tumor 30.5 SYP GFAP ENO2
27 papilloma of choroid plexus 30.5 TTR SYP MUC1 GFAP ENO2
28 adenoma 30.5 TSC1 MUC1 MGMT MEN1
29 medulloepithelioma 30.5 VIM SYP NES GFAP
30 ganglioneuroma 30.5 SYP GFAP ENO2
31 pilomyxoid astrocytoma 30.4 SYP NF1 GFAP
32 lipomatosis, multiple 30.4 NF1 MEN1 MDM2
33 neurofibromatosis, type iv, of riccardi 30.4 TSC2 PDGFRA NF2 NF1 MTOR MEN1
34 paraganglioma 30.3 SYP NF1 MEN1 GFAP ENO2
35 rhabdoid meningioma 30.3 VIM SYP NF2 GFAP ENO2
36 pineal gland cancer 30.3 SYP NES GFAP ENO2
37 choroid plexus cancer 30.3 TTR SYP GFAP
38 hemangioblastoma 30.3 VIM SYP MUC1 GFAP ENO2 EGFR
39 gliofibroma 30.3 SYP NF1 GFAP
40 spinal cord astrocytoma 30.2 MGMT GFAP
41 islet cell tumor 30.2 SYP MEN1 ENO2
42 fibrillary astrocytoma 30.2 PDGFRA NF1 MGMT GFAP EGFR
43 malignant glioma 30.2 MGMT MDM2 HOTAIR GFAP EGFR
44 rhabdoid tumor predisposition syndrome 1 30.2 VIM SYP MUC1
45 papillary tumor of the pineal region 30.2 VIM SYP MUC1 ENO2
46 granular cell tumor 30.1 VIM SYP GFAP ENO2
47 obstructive hydrocephalus 30.0 TSC2 TSC1 SYP NF2 NF1 GFAP
48 li-fraumeni syndrome 30.0 NF1 MEN1 MDM2 EGFR
49 spindle cell sarcoma 30.0 VIM NF2 MUC1 MDM2
50 chordoid meningioma 30.0 VIM SYP MUC1 GFAP

Graphical network of the top 20 diseases related to Benign Ependymoma:



Diseases related to Benign Ependymoma

Symptoms & Phenotypes for Benign Ependymoma

Human phenotypes related to Benign Ependymoma:

31 (show all 15)
# Description HPO Frequency HPO Source Accession
1 ependymoma 31 obligate (100%) HP:0002888
2 migraine 31 frequent (33%) HP:0002076
3 pain 31 frequent (33%) HP:0012531
4 abnormal cell morphology 31 frequent (33%) HP:0025461
5 seizures 31 occasional (7.5%) HP:0001250
6 gait disturbance 31 occasional (7.5%) HP:0001288
7 vomiting 31 occasional (7.5%) HP:0002013
8 spinal cord tumor 31 occasional (7.5%) HP:0010302
9 distal muscle weakness 31 occasional (7.5%) HP:0002460
10 dysesthesia 31 occasional (7.5%) HP:0012534
11 supratentorial neoplasm 31 occasional (7.5%) HP:0030693
12 neoplasm of the lung 31 very rare (1%) HP:0100526
13 ovarian neoplasm 31 very rare (1%) HP:0100615
14 neoplasm of the breast 31 very rare (1%) HP:0100013
15 neoplasm of the liver 31 very rare (1%) HP:0002896

UMLS symptoms related to Benign Ependymoma:


back pain

GenomeRNAi Phenotypes related to Benign Ependymoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased cell migration GR00055-A-1 9.5 EGFR MTOR MUC1 NF1 NF2 TSC1
2 Decreased viability with paclitaxel GR00179-A-1 9.02 EGFR MTOR
3 Decreased viability with paclitaxel GR00179-A-2 9.02 MTOR
4 Decreased viability with paclitaxel GR00179-A-3 9.02 EGFR MTOR

MGI Mouse Phenotypes related to Benign Ependymoma:

45 (show all 17)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.35 DCX ENO2 GFAP MDM2 MTOR NF1
2 cellular MP:0005384 10.33 CDKN2B EGFR ENO2 GFAP MDM2 MEN1
3 homeostasis/metabolism MP:0005376 10.32 CDKN2B EGFR GFAP MDM2 MEN1 MGMT
4 cardiovascular system MP:0005385 10.3 EGFR GFAP MDM2 MEN1 MTOR NF1
5 mortality/aging MP:0010768 10.3 CDKN2B DCX EGFR GFAP MDM2 MEN1
6 growth/size/body region MP:0005378 10.27 DCX EGFR ENO2 GFAP MDM2 MEN1
7 endocrine/exocrine gland MP:0005379 10.25 CDKN2B EGFR MDM2 MEN1 MGMT MTOR
8 nervous system MP:0003631 10.24 DCX EGFR ENO2 GFAP MDM2 MEN1
9 embryo MP:0005380 10.22 EGFR MDM2 MEN1 MTOR NF1 NF2
10 neoplasm MP:0002006 10.1 CDKN2B EGFR MDM2 MEN1 MGMT NF1
11 muscle MP:0005369 10.09 EGFR GFAP MDM2 MEN1 MTOR NF1
12 craniofacial MP:0005382 10.08 EGFR ENO2 MDM2 MEN1 NF1 NF2
13 no phenotypic analysis MP:0003012 9.87 CDKN2B EGFR MDM2 MGMT MTOR PDGFRA
14 renal/urinary system MP:0005367 9.85 CDKN2B EGFR MDM2 MTOR NF1 NF2
15 reproductive system MP:0005389 9.7 CDKN2B DCX EGFR MDM2 MEN1 NF1
16 pigmentation MP:0001186 9.65 EGFR MDM2 NF1 PDGFRA TSC1
17 respiratory system MP:0005388 9.28 EGFR ENO2 MGMT MTOR NF1 NF2

Drugs & Therapeutics for Benign Ependymoma

Drugs for Benign Ependymoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 300)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Temozolomide Approved, Investigational Phase 2, Phase 3 85622-93-1 5394
2
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
3
Donepezil Approved Phase 3 120014-06-4 3152
4
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
5
Ondansetron Approved Phase 3 99614-02-5 4595
6
Granisetron Approved, Investigational Phase 3 109889-09-0 3510
7
Valproic acid Approved, Investigational Phase 2, Phase 3 99-66-1 3121
8
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
9
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
10
Histamine Approved, Investigational Phase 3 51-45-6 774
11
Cyproheptadine Approved Phase 3 129-03-3 2913
12 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
13 Trofosfamide Investigational Phase 2, Phase 3 22089-22-1
14
Emodepside Investigational, Vet_approved Phase 3 155030-63-0
15 Nootropic Agents Phase 3
16 Cholinergic Agents Phase 3
17 Cholinesterase Inhibitors Phase 3
18 Cola Phase 3
19 Narcotics Phase 3
20 Anesthetics, General Phase 3
21 Analgesics, Opioid Phase 3
22 Adjuvants, Anesthesia Phase 3
23 Anesthetics, Intravenous Phase 3
24 Analgesics Phase 3
25 Emetics Phase 3
26 Anticonvulsants Phase 2, Phase 3
27 Central Nervous System Depressants Phase 2, Phase 3
28 Psychotropic Drugs Phase 2, Phase 3
29 Tranquilizing Agents Phase 2, Phase 3
30 GABA Agents Phase 2, Phase 3
31 Antimanic Agents Phase 2, Phase 3
32 Podophyllotoxin Phase 3 518-28-5
33 Dermatologic Agents Phase 3
34 Neurotransmitter Agents Phase 3
35 Central Nervous System Stimulants Phase 3
36 Dopamine Uptake Inhibitors Phase 3
37 Dexmethylphenidate Hydrochloride Phase 3
38 Dopamine Agents Phase 3
39 Histamine H1 Antagonists Phase 3
40 Antipruritics Phase 3
41
Histamine Phosphate Phase 3 51-74-1 65513
42 Histamine Antagonists Phase 3
43 Anti-Allergic Agents Phase 3
44 Serotonin Antagonists Phase 3
45 Serotonin Agents Phase 3
46
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
47
Aminolevulinic acid Approved Phase 2 106-60-5 137
48
Mannitol Approved, Investigational Phase 2 69-65-8 453 6251
49
Cyclophosphamide Approved, Investigational Phase 2 50-18-0, 6055-19-2 2907
50
Tamoxifen Approved Phase 2 10540-29-1 2733526

Interventional clinical trials:

(show top 50) (show all 266)
# Name Status NCT ID Phase Drugs
1 Dose Intensive Chemotherapy for Children Less Than Ten Years of Age Newly-Diagnosed With Malignant Brain Tumors: A Pilot Study of Two Alternative Intensive Induction Chemotherapy Regimens, Followed by Consolidation With Myeloablative Chemotherapy (Thiotepa and Carboplatin, With or Without Etoposide) and Autologous Stem Cell Rescue [HEAD START III] Unknown status NCT00392886 Phase 3 carboplatin;cisplatin;cyclophosphamide;etoposide;methotrexate;temozolomide;thiotepa;vincristine sulfate
2 Efficacy of Stereotactic Conformal Radiotherapy (SCRT) Compared to Conventional Radiotherapy in Minimising Late Sequelae in Children and Young Adults With Brain Tumours: a Randomised Clinical Trial Unknown status NCT00517959 Phase 3
3 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
4 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
5 Randomized Controlled Trial of Acupressure to Control Chemotherapy-Induced Nausea (CIN) in Children Receiving Highly Emetogenic Chemotherapy Completed NCT01346267 Phase 3
6 Therapy-Optimization Trial and Phase II Study for the Treatment of Relapsed or Refractory of Primitive Neuroectodermal Brain Tumors and Ependymomas in Children and Adolescents Completed NCT00749723 Phase 2, Phase 3 carboplatin;etoposide;temozolomide;thiotepa, carboplatin, etoposide;temozolomide, thiotepa;intraventricular etoposide;trofosfamide, etoposide
7 An International Clinical Program for the Diagnosis and Treatment of Children, Adolescents and Young Adults With Ependymoma Recruiting NCT02265770 Phase 2, Phase 3 16 weeks of VEC + CDDP;VEC + HD-MTX;Chemotherapy + Valproate;VEC;Chemotherapy
8 Phase III Randomized Trial of Post-Radiation Chemotherapy in Patients With Newly Diagnosed Ependymoma Ages 1 to 21 Years Active, not recruiting NCT01096368 Phase 3 Carboplatin;Cisplatin;Cyclophosphamide;Etoposide;Vincristine Sulfate Liposome
9 A Phase III, Double-Blind, Prospective Randomized Clinical Trial of the Effect of D-threo-methylphenidate HCl (d-MPH) on Quality of Life in Brain Tumor Patients Receiving Radiation Therapy Terminated NCT00031798 Phase 3 methylphenidate hydrochloride
10 Prevention of Cancer/Treatment-Related Weight Loss in Children at High Nutritional Risk Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
11 Phase II Study of Intravenous Etoposide in Patients With Relapsed Ependymoma Unknown status NCT00278252 Phase 2 etoposide
12 Phase II Study of High-Dose Methotrexate in Children With Residual Ependymoma Unknown status NCT00287924 Phase 2 methotrexate
13 A Phase 2 Study of Aminolevulinic Acid (ALA) to Enhance Visualization and Resection of Malignant Glial Tumors of the Brain Unknown status NCT01403311 Phase 2 5-Aminolevuline Acid
14 Management of Children Aged Less Than 3 Years With Brain Tumors Unknown status NCT00281905 Phase 2 carboplatin;cisplatin;cyclophosphamide;methotrexate;vincristine sulfate
15 Phase I/II Clinical Trial of the Safety, Tolerability, and Anti-tumor Efficacy of the IGF-1R Inhibitor, AXL1717 (Picropodophyllin), in the Treatment of Recurrent Malignant Astrocytomas Unknown status NCT01721577 Phase 1, Phase 2 AXL1717
16 Phase I/II Study of Intratumoral Injection of DTI-015 Prior to Tumor Resection in Patients With Recurrent Malignant Glioma or Metastatic Neoplasm to Brain Unknown status NCT00009854 Phase 1, Phase 2 carmustine in ethanol
17 Proton Radiation for Low Grade Gliomas Unknown status NCT01024907 Phase 1, Phase 2
18 Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) Unknown status NCT02819479 Phase 2 25% Mannitol;Low-dose Intra-arterial Bevacizumab
19 A Phase II Trial of Continuous Low-Dose Temozolomide for Patients With Recurrent Malignant Glioma Completed NCT00498927 Phase 2 temozolomide
20 A PHASE II TRIAL OF ETOPOSIDE AND CISPLATIN IN THE TREATMENT OF RECURRENT EPENDYMOMAS Completed NCT00002876 Phase 2 cisplatin;etoposide
21 PHASE I STUDY OF ANTI-TENASCIN MONOCLONAL ANTIBODY 131I 81C6 VIA SURGICALLY CREATED CYSTIC RESECTION CAVITY IN THE TREATMENT OF PATIENTS WITH PRIMARY OR METASTATIC MALIGNANT BRAIN TUMORS Completed NCT00002752 Phase 1, Phase 2
22 Dose Intensive Chemotherapy for Patients Greater Than or Equal To 10 Years of Age With Newly Diagnosed High Stage Medulloblastoma, Supratentorial Primitive Neuroectodermal Tumors (PNET) and Ependymoma: A Feasibility Study of an Intensive Induction Chemotherapy Regimen Followed by Standard Irradiation Completed NCT00006258 Phase 2 cisplatin;cyclophosphamide;etoposide;methotrexate;vincristine sulfate
23 Improved Characterization of Brain Tumors By MRI and MRS Completed NCT00274755 Phase 2 chemotherapy
24 Cisplatin, Doxorubicin and Tamoxifen in the Treatment of Incurable Soft Tissue and Endocrine Malignancies Completed NCT00002608 Phase 2 cisplatin;doxorubicin hydrochloride;tamoxifen citrate
25 A Pilot Study of Tamoxifen, Carboplatin and Topotecan in the Treatment of Recurrent or Refractory Primary Brain or Spinal Cord Tumors or Metastatic Epithelial Cancers With Central Nervous System Metastases Completed NCT00541138 Phase 2 carboplatin;tamoxifen citrate;topotecan hydrochloride
26 Donepezil and EGb761 in Improving Neurocognitive Function in Patients Who Have Previously Undergone Radiation Therapy for Primary Brain Tumor or Brain Metastases Completed NCT00070161 Phase 2 donepezil hydrochloride
27 A Feasibility Study of Armodafinil for Brain Radiation-Induced Fatigue Completed NCT01032200 Phase 2 Armodafinil
28 SIOP Study of Combined Modality Treatment in Childhood Ependymoma Completed NCT00004224 Phase 2 cyclophosphamide;etoposide;vincristine sulfate
29 A Phase II Study of Pemetrexed in Children With Recurrent Malignancies Completed NCT00520936 Phase 2 pemetrexed
30 A Phase II Trial of Preradiation Multiagent Chemotherapy for Adults With "Poor Risk" Medulloblastoma, PNET, and Disseminated Ependymoma Completed NCT00003309 Phase 2 cisplatin;cyclophosphamide;etoposide;vincristine sulfate
31 A Phase II Trial of Conformal Radiation Therapy for Pediatric Patients With Localized Ependymoma, Chemotherapy Prior to Second Surgery for Incompletely Resected Ependymoma and Observation for Completely Resected, Differentiated, Supratentorial Ependymoma Completed NCT00027846 Phase 2 carboplatin;cyclophosphamide;etoposide;vincristine sulfate;Mesna
32 A Phase II Study of Image-Guided Radiation Therapy for Pediatric CNS Tumors and Quantification of Radiation-Related CNS Effects Completed NCT00187226 Phase 2
33 CAMP 013:- Tandem Thiotepa Regimen For Selected Malignant Gliomas:1) Primary Or Recurrent Glioblastoma Multiforme (GBM); and 2) Recurrent Anaplastic Astrocytomas (AA), Oligodendrogliomas (O), Oligoastrocytomas (OA), Ependymomas And Primitive Neuroectodermal Tumors (PNET) That Have Either Progressed After Primary Therapy Or Are Refractory To Standard Chemotherapy Completed NCT00008008 Phase 2 cyclophosphamide;thiotepa
34 A Phase II Study of Sunitinib (NSC# 736511) in Recurrent, Refractory or Progressive High Grade Glioma and Ependymoma Tumors in Pediatric and Young Adult Patients Completed NCT01462695 Phase 2 Sunitinib Malate
35 A Phase II Trial of Rebeccamycin Analogue (NSC #655649) in Children With Solid Tumors Completed NCT00006102 Phase 2 becatecarin
36 Phase II Treatment of Children With Newly Diagnosed Malignant Central Nervous System Tumors With Temozolomide Prior to Radiation Therapy Completed NCT00005955 Phase 2 temozolomide
37 Phase II Trial of Irinotecan in Children With Refractory Solid Tumors Completed NCT00004078 Phase 2 irinotecan hydrochloride
38 Phase II Study of Everolimus (RAD001, Afinitor®) for Children With Recurrent or Progressive Ependymoma Completed NCT02155920 Phase 2 Everolimus
39 Molecular Biology and Phase II Study of Lapatinib (GW572016) in Pediatric Patients With Recurrent or Refractory Medulloblastoma, Malignant Glioma or Ependymoma Completed NCT00095940 Phase 1, Phase 2 lapatinib ditosylate
40 A Phase II Study of Dose-Dense Temozolomide and Lapatinib for Recurrent Low-Grade and Anaplastic Supratentorial, Infratentorial and Spinal Cord Ependymoma Completed NCT00826241 Phase 2 Temozolomide;Lapatinib
41 Phase II Trial Of High Dose Cyclophosphamide, Cisplatin And Carmustine With Stem Cell Reconstitution Followed By Specific Cellular Therapy In Patients With Recurrent Or Refractory Brain Tumors Completed NCT00014573 Phase 2 carmustine;cisplatin;cyclophosphamide;paclitaxel
42 Phase II Study of Methotrexate, Mechlorethamine, Vincristine, Prednisone, and Procarbazine (MMOPP) as Primary Therapy in Infants or Young Children With Primitive Neuroectodermal Tumors or High-Grade Astrocytoma Completed NCT00002463 Phase 2 MOPP Regimen;Leucovorin Calcium;Mechlorethamine Hydrochloride;Methotrexate;Prednisone;Procarbazine Hydrochloride;Vincristine Sulfate
43 Phase II Study of Bevacizumab Plus Irinotecan (Camptosar™) in Children With Recurrent, Progressive, or Refractory Malignant Gliomas, Diffuse/Intrinsic Brain Stem Gliomas, Medulloblastomas, Ependymomas and Low Grade Gliomas Completed NCT00381797 Phase 2 Irinotecan Hydrochloride
44 Phase II Study of Phenylacetate in Pediatric Patients With Central Nervous System Tumors Completed NCT00003241 Phase 2 phenylacetate
45 Levetiracetam and Pregabalin for Monotherapy in Patients With Brain Tumors and Seizures. A Phase II Randomized Study. Completed NCT00629889 Phase 2 levetiracetam;pregabalin
46 A Phase II Study of Bevacizumab and Lapatinib in Children With Recurrent or Refractory Ependymoma Completed NCT00883688 Phase 2 Bevacizumab;Lapatinib
47 A Phase II Trial of Intravenous Cereport (RMP-7) and Carboplatin in Childhood Brain Tumors Completed NCT00019422 Phase 2 carboplatin;lobradimil
48 The Effect of Cyproheptadine Hydrochloride (Periactin) and Megestrol Acetate (Megace) on Weight in Children With Cancer/Treatment Related Cachexia Completed NCT00066248 Phase 2 cyproheptadine hydrochloride;megestrol acetate
49 A Phase II Trial of Poly ICLC in Patients With Recurrent Anaplastic Glioma Completed NCT00058123 Phase 2 poly ICLC
50 A Phase II Study of Oxaliplatin in Children With Recurrent Solid Tumors Completed NCT00091182 Phase 2 oxaliplatin

Search NIH Clinical Center for Benign Ependymoma

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine

Cochrane evidence based reviews: ependymoma

Genetic Tests for Benign Ependymoma

Anatomical Context for Benign Ependymoma

MalaCards organs/tissues related to Benign Ependymoma:

40
Brain, Spinal Cord, Pituitary, T Cells, Lung, Kidney, Pineal

Publications for Benign Ependymoma

Articles related to Benign Ependymoma:

(show top 50) (show all 3677)
# Title Authors PMID Year
1
Promoter methylation and expression analysis of MGMT in advanced pediatric brain tumors. 54 61
19724855 2009
2
Podoplanin is a potential marker for the diagnosis of ependymoma: a comparative study with epithelial membrane antigen (EMA). 54 61
19788053 2009
3
[Expression of epidermal growth factor receptor and Ki-67 antigen in brain ependymoma and the correlation between them]. 54 61
19257969 2008
4
EGFR tyrosine kinase inhibition radiosensitizes and induces apoptosis in malignant glioma and childhood ependymoma xenografts. 54 61
18386816 2008
5
Olig2 and CD99 are useful negative markers for the diagnosis of brain tumors. 54 61
18552083 2008
6
Nestin expression in different tumours and its relevance to malignant grade. 54 61
17873113 2008
7
Immunohistochemical study of CD99 and EMA expression in ependymomas. 54 61
18382710 2008
8
Frequent but borderline methylation of p16 (INK4a) and TIMP3 in medulloblastoma and sPNET revealed by quantitative analyses. 54 61
17206475 2007
9
New immunohistochemical markers in the evaluation of central nervous system tumors: a review of 7 selected adult and pediatric brain tumors. 54 61
17284108 2007
10
Immunohistochemical profile and chromosomal imbalances in papillary tumours of the pineal region. 54 61
16640646 2006
11
p53 Pathway dysfunction in primary childhood ependymomas. 54 61
16086408 2006
12
Methylation of RASSF1A and TRAIL pathway-related genes is frequent in childhood intracranial ependymomas and benign choroid plexus papilloma. 54 61
16616114 2006
13
Identification of gains on 1q and epidermal growth factor receptor overexpression as independent prognostic markers in intracranial ependymoma. 54 61
16609018 2006
14
Survivin expression in intracranial ependymomas and its correlation with tumor cell proliferation and patient outcome. 54 61
16146813 2005
15
Epigenetic inactivation of the RASSF1A tumour suppressor gene in ependymoma. 54 61
16051033 2005
16
A PDGFRA promoter polymorphism, which disrupts the binding of ZNF148, is associated with primitive neuroectodermal tumours and ependymomas. 54 61
15635072 2005
17
Light microscopic demonstration of the microlumen of ependymoma: a study of the usefulness of antigen retrieval for epithelial membrane antigen (EMA) immunostaining. 54 61
15696964 2004
18
Sensitivity and specificity of epithelial membrane antigen staining patterns in ependymomas. 54 61
12898159 2003
19
March 2003: a 41 -year-old female with a solitary lesion in the liver. 54 61
12946033 2003
20
Complex cytogenetic abnormalities including telomeric associations and MEN1 mutation in a pediatric ependymoma. 54 61
12505253 2002
21
The expression of p73, p21 and MDM2 proteins in gliomas. 54 61
12241107 2002
22
Immunohistochemical markers for prognosis of ependymal neoplasms. 54 61
12187959 2002
23
Differential involvement of protein 4.1 family members DAL-1 and NF2 in intracranial and intraspinal ependymomas. 54 61
12011257 2002
24
Analysis of the NF2 gene in oligodendrogliomas and ependymomas. 54 61
11996787 2002
25
p14ARF protein (FL-132) immunoreactivity in intracranial ependymomas and its prognostic significance: an analysis of 103 cases. 54 61
11585252 2001
26
Telomerase activity and expression of telomerase reverse transcriptase correlated with cell proliferation in meningiomas and malignant brain tumors in vivo. 54 61
11561758 2001
27
Mutation analysis of the p73 gene in nonastrocytic brain tumours. 54 61
11461077 2001
28
Molecular genetic alterations on chromosomes 11 and 22 in ependymomas. 54 61
11275983 2001
29
Immunohistochemical markers for intracranial ependymoma recurrence. An analysis of 88 cases. 54 61
10967185 2000
30
Receptor-mediated endocytosis of transthyretin by ependymoma cells. 54 61
10869517 2000
31
The immunophenotype of ependymomas. 54 61
10937045 2000
32
Ovarian ependymoma. A case report. 54 61
10982025 2000
33
Low frequency of SV40, JC and BK polyomavirus sequences in human medulloblastomas, meningiomas and ependymomas. 54 61
10668898 2000
34
Evidence for an ependymoma tumour suppressor gene in chromosome region 22pter-22q11.2. 54 61
10584875 1999
35
Expression of the simian virus 40 large tumor antigen (Tag) and formation of Tag-p53 and Tag-pRb complexes in human brain tumors. 54 61
10570441 1999
36
Atypical central neurocytoma: report of a case. 54 61
10502912 1999
37
Cerebellar papillary meningioma in a 3-year-old boy: the usefulness of electron microscopy for diagnosis. 54 61
10403309 1999
38
Molecular genetic analysis of non-astrocytic gliomas. 54 61
10231401 1999
39
Signet-ring cell ependymoma: case report with implications for pathogenesis and differential diagnosis. 54 61
10631722 1999
40
Tissue culture of human neurocytomas induces the expression of glial fibrilary acidic protein. 54 61
10451427 1998
41
O6-Methylguanine-DNA methyltransferase protein levels in pediatric brain tumors. 54 61
9815647 1997
42
Expression of telomerase RNA component correlates with the MIB-1 proliferation index in ependymomas. 54 61
9329458 1997
43
Paraganglioma of the cauda equina. A case report and review of the literature. 54 61
8611199 1996
44
The ultrastructure of ependymoma: personal experience and the review of the literature. 54 61
9812425 1996
45
Loss of heterozygosity on chromosome 10, 13q(Rb), 17p, and p53 gene mutations in human brain gliomas. 54 61
8924230 1995
46
Expression of non-glial intermediate filament proteins in gliomas. 54 61
7518371 1994
47
Ki-67 immunoreactivity in human central nervous system tumors: a study with MIB 1 monoclonal antibody on archival material. 54 61
7511316 1994
48
Cauda equina tumor with ependymal and paraganglionic differentiation. 54 61
1612583 1992
49
Epidermal growth factor receptor in human brain tumors. 54 61
1560188 1992
50
[Immunohistochemical study for choroid plexus papillomas and ependymomas]. 54 61
1726244 1991

Variations for Benign Ependymoma

ClinVar genetic disease variations for Benign Ependymoma:

6 (show all 37) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 MEN1 NM_000244.3(MEN1):c.711dup (p.Lys238fs)duplication Pathogenic 487778 rs1555165565 11:64575111-64575111 11:64807638-64807639
2 NF2 NM_016418.5(NF2):c.551G>A (p.Trp184Ter)SNV Likely pathogenic 487796 rs1555993293 22:30051617-30051617 22:29655628-29655628
3 subset of 76 genes: MEN1 dup(11)(q13.1q13.1)duplication Likely pathogenic 634998 11:63533279-65429676
4 MSH6 NM_001281493.1(MSH6):c.-41_-40delinsAAindel Conflicting interpretations of pathogenicity 89572 rs267608079 2:48025988-48025989 2:47798849-47798850
5 RET NM_020975.6(RET):c.1699G>A (p.Asp567Asn)SNV Conflicting interpretations of pathogenicity 136103 rs147219360 10:43608351-43608351 10:43112903-43112903
6 LATS1 NM_004690.4(LATS1):c.2365G>C (p.Asp789His)SNV Uncertain significance 487797 rs750318192 6:150001239-150001239 6:149680103-149680103
7 MAP4K3 NM_003618.4(MAP4K3):c.899T>C (p.Phe300Ser)SNV Uncertain significance 487798 rs1268580645 2:39552678-39552678 2:39325537-39325537
8 TRAF3 NM_003300.4(TRAF3):c.53C>G (p.Pro18Arg)SNV Uncertain significance 487799 rs145456077 14:103336591-103336591 14:102870254-102870254
9 LETM1 NM_012318.3(LETM1):c.286G>A (p.Val96Met)SNV Uncertain significance 487800 rs753905629 4:1843382-1843382 4:1841655-1841655
10 TXNRD2 NM_006440.5(TXNRD2):c.1432G>C (p.Ala478Pro)SNV Uncertain significance 487801 rs1555906972 22:19865626-19865626 22:19878103-19878103
11 HSD3B2 NM_000198.4(HSD3B2):c.1004G>A (p.Arg335Gln)SNV Uncertain significance 487802 rs985808078 1:119965128-119965128 1:119422505-119422505
12 GLB1 NM_000404.4(GLB1):c.1903G>C (p.Ala635Pro)SNV Uncertain significance 487803 rs1553604701 3:33038668-33038668 3:32997176-32997176
13 MT-ND4 NC_012920.1:m.11032delAdeletion Uncertain significance 487804 rs1556423884 MT:11032-11032 MT:11032-11032
14 SYNE1 NM_182961.4(SYNE1):c.11097C>G (p.Phe3699Leu)SNV Uncertain significance 487805 rs1554520414 6:152674554-152674554 6:152353419-152353419
15 ADGRA2 NM_032777.10(ADGRA2):c.1316_1334del (p.Asn439fs)deletion Uncertain significance 487806 rs1554525957 8:37691223-37691241 8:37833705-37833723
16 CACNG2 NM_006078.4(CACNG2):c.541T>C (p.Tyr181His)SNV Uncertain significance 487807 rs1555892196 22:36960829-36960829 22:36564782-36564782
17 SH3TC2 NM_024577.3(SH3TC2):c.3016del (p.Ser1006fs)deletion Uncertain significance 487808 rs1554121513 5:148406172-148406172 5:149026609-149026609
18 SLC39A11 NM_139177.4(SLC39A11):c.595G>T (p.Val199Phe)SNV Uncertain significance 487809 rs745762301 17:70845779-70845779 17:72849640-72849640
19 TRPM1 NM_001252024.2(TRPM1):c.283A>C (p.Ile95Leu)SNV Uncertain significance 487810 rs1555424877 15:31360292-31360292 15:31068089-31068089
20 RET NM_020975.6(RET):c.1202G>A (p.Ser401Asn)SNV Uncertain significance 620604 rs1564493414 10:43604617-43604617 10:43109169-43109169
21 GON4L NM_032292.6(GON4L):c.2455A>G (p.Asn819Asp)SNV Uncertain significance 487779 rs1553200563 1:155742897-155742897 1:155773106-155773106
22 HDAC3 NM_003883.4(HDAC3):c.50_55+5deldeletion Uncertain significance 487780 rs1554218152 5:141016298-141016308 5:141636731-141636741
23 SETD9 NM_153706.4(SETD9):c.788_796del (p.Ile263_Tyr265del)deletion Uncertain significance 487781 rs1554039146 5:56210766-56210774 5:56914939-56914947
24 BANP NM_079837.3(BANP):c.575A>G (p.Asn192Ser)SNV Uncertain significance 487782 rs1555586650 16:88052070-88052070 16:88018464-88018464
25 SUV39H1 NM_003173.4(SUV39H1):c.415C>T (p.Arg139Cys)SNV Uncertain significance 487783 rs368779259 X:48558731-48558731 X:48700340-48700340
26 TASOR NM_001112736.2(TASOR):c.97G>A (p.Glu33Lys)SNV Uncertain significance 487784 rs1553733337 3:56716938-56716938 3:56682910-56682910
27 POU3F4 NM_000307.5(POU3F4):c.1013C>T (p.Pro338Leu)SNV Uncertain significance 487785 rs1555984638 X:82764345-82764345 X:83509337-83509337
28 PATZ1 NM_014323.3(PATZ1):c.562G>T (p.Asp188Tyr)SNV Uncertain significance 487786 rs1555894069 22:31741027-31741027 22:31345041-31345041
29 KAT6B NM_012330.4(KAT6B):c.3827C>T (p.Pro1276Leu)SNV Uncertain significance 487787 rs1554845417 10:76788409-76788409 10:75028651-75028651
30 KREMEN2 NM_172229.3(KREMEN2):c.494G>T (p.Gly165Val)SNV Uncertain significance 487788 rs1210829529 16:3016650-3016650 16:2966649-2966649
31 DEPDC5 NM_001242897.2(DEPDC5):c.2705G>A (p.Trp902Ter)SNV Uncertain significance 487789 rs1555900957 22:32241141-32241141 22:31845155-31845155
32 NET1 NM_001047160.3(NET1):c.498G>T (p.Glu166Asp)SNV Uncertain significance 487790 rs1554818513 10:5494455-5494455 10:5452492-5452492
33 SPRY3 NM_005840.2(SPRY3):c.55C>T (p.Arg19Cys)SNV Uncertain significance 487791 rs779201129 X:155003588-155003588 X:155773926-155773926
34 VBP1 NM_003372.7(VBP1):c.331C>A (p.Leu111Met)SNV Uncertain significance 487792 rs1000821034 X:154456711-154456711 X:155228429-155228429
35 ARHGAP32 NM_014715.4(ARHGAP32):c.3656C>G (p.Thr1219Ser)SNV Uncertain significance 487793 rs749174548 11:128840363-128840363 11:128970468-128970468
36 OTUD5 NM_017602.4(OTUD5):c.1702C>A (p.Pro568Thr)SNV Uncertain significance 487794 rs1295653938 X:48780465-48780465 X:48923188-48923188
37 KLHL21 NM_014851.4(KLHL21):c.501G>C (p.Glu167Asp)SNV Uncertain significance 487795 rs1292721663 1:6662377-6662377 1:6602317-6602317

Cosmic variations for Benign Ependymoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM99575217 central nervous system,fourth ventricle,glioma,ependymoma Grade III-IV c.1428G>A p.W476* 11:64804754-64804754 4

Copy number variations for Benign Ependymoma from CNVD:

7 (show top 50) (show all 1024)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13823 1 1 7200000 Deletion Ependymoma
2 15495 1 116080654 116108285 Amplification NHLH2 Ependymoma
3 15648 1 117745152 117779348 Deletion MAN1A2 Ependymoma
4 19381 1 150034000 245120000 Amplification Ependymoma
5 19382 1 150034000 245120000 Amplification Ependymoma
6 26308 1 198898833 198920273 Amplification LGR6 Ependymoma
7 31595 1 2869431 2902617 Amplification TLR5 Ependymoma
8 31803 1 3118000 5001000 Deletion Ependymoma
9 38299 10 101279725 101300855 Deletion NKX2 Ependymoma
10 38453 10 102724768 102752246 Deletion LZTS2 Ependymoma
11 38454 10 102724768 102752246 Deletion MRPL43 Ependymoma
12 38455 10 102724768 102752246 Deletion PEO1 Ependymoma
13 38456 10 102724768 102752246 Deletion SEMA4G Ependymoma
14 38866 10 105634726 105742493 Deletion OBFC1 Ependymoma
15 38867 10 105634726 105742493 Deletion SLK Ependymoma
16 38979 10 106855945 106907237 Deletion SORCS3 Ependymoma
17 39169 10 11151805 11236375 Deletion CUGBP2 Ependymoma
18 40763 10 13344307 13497936 Deletion PHYH Ependymoma
19 40764 10 13344307 13497936 Deletion SEPHS1 Ependymoma
20 40806 10 133827559 133847021 Amplification C10orf39 Ependymoma
21 40809 10 133852261 133910912 Deletion DPYSL4 Ependymoma
22 40810 10 133852261 133910912 Deletion STK32C Ependymoma
23 40887 10 134410586 134892955 Deletion C10orf92 Ependymoma
24 40888 10 134410586 134892955 Deletion C10orf93 Ependymoma
25 40889 10 134410586 134892955 Deletion GPR123 Ependymoma
26 40890 10 134410586 134892955 Deletion INPP5A Ependymoma
27 40891 10 134410586 134892955 Deletion KNDC1 Ependymoma
28 40892 10 134410586 134892955 Deletion NKX6 Ependymoma
29 41033 10 135073302 135095235 Amplification ECHS1 Ependymoma
30 41034 10 135073302 135095235 Amplification PAOX Ependymoma
31 41074 10 135176625 135276748 Deletion CYP2E1 Ependymoma
32 41075 10 135176625 135276748 Deletion FLJ44653 Ependymoma
33 41076 10 135176625 135276748 Deletion SYCE1 Ependymoma
34 41910 10 25665327 25756077 Deletion GPR158 Ependymoma
35 42307 10 3169189 3180797 Deletion PITRM1 Ependymoma
36 44077 10 5175582 5187881 Deletion AKR1CL1 Ependymoma
37 44224 10 53651276 53712562 Deletion PRKG1 Ependymoma
38 44704 10 6170011 6268419 Deletion RBM17 Ependymoma
39 45199 10 68970214 69114993 Deletion CTNNA3 Ependymoma
40 45273 10 69645873 69701073 Deletion ATOH7 Ependymoma
41 45408 10 70846341 70896472 Deletion TSPAN15 Ependymoma
42 45468 10 71234506 71351772 Deletion COL13A1 Ependymoma
43 45538 10 71990162 72295747 Deletion ADAMTS14 Ependymoma
44 45539 10 71990162 72295747 Deletion C10orf27 Ependymoma
45 45540 10 71990162 72295747 Deletion KIAA1274 Ependymoma
46 45541 10 71990162 72295747 Deletion PRF1 Ependymoma
47 45542 10 71990162 72295747 Deletion SGPL1 Ependymoma
48 45578 10 72636128 72774965 Deletion SLC29A3 Ependymoma
49 45579 10 72636128 72774965 Deletion UNC5B Ependymoma
50 45628 10 73121579 73231404 Deletion C10orf54 Ependymoma

Expression for Benign Ependymoma

Search GEO for disease gene expression data for Benign Ependymoma.

Pathways for Benign Ependymoma

Pathways related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.68 VIM TSC2 TSC1 PDGFRA NF1 MUC1
2
Show member pathways
12.9 TSC2 TSC1 PDGFRA MTOR MDM2 EGFR
3
Show member pathways
12.82 TSC2 TSC1 PDGFRA MTOR MDM2 EGFR
4 12.76 PDGFRA MTOR MDM2 EGFR CDKN2B
5
Show member pathways
12.64 TSC2 PDGFRA MTOR MDM2 EGFR
6
Show member pathways
12.51 PDGFRA NF1 MTOR MDM2 EGFR
7
Show member pathways
12.42 MUC1 MTOR MDM2 EGFR
8 12.42 SYP NF2 NF1 GFAP ENO2 DCX
9 12.38 VIM PDGFRA MTOR MDM2 EGFR
10
Show member pathways
12.36 PDGFRA MTOR MDM2 EGFR
11
Show member pathways
12.34 TSC2 TSC1 PDGFRA MTOR EGFR
12
Show member pathways
12.3 TSC2 TSC1 MTOR MDM2
13
Show member pathways
12.23 PDGFRA MTOR GFAP EGFR
14
Show member pathways
12.22 TSC2 TSC1 PDGFRA MTOR EGFR
15
Show member pathways
12.15 TSC2 TSC1 PDGFRA NF1 MTOR MDM2
16
Show member pathways
11.99 TSC2 MTOR MDM2 EGFR
17
Show member pathways
11.98 TSC2 TSC1 PDGFRA MTOR MDM2 EGFR
18 11.97 TSC2 TSC1 MTOR MDM2 CDKN2B
19 11.82 TSC2 TSC1 NF1 MTOR MDM2 EGFR
20 11.73 TSC2 TSC1 MTOR
21
Show member pathways
11.73 TSC2 MTOR MDM2
22 11.62 PDGFRA MTOR EGFR
23 11.55 TSC2 TSC1 MTOR
24 11.55 VIM SYP PDGFRA NES GFAP
25 11.48 TSC2 TSC1 MTOR
26 11.34 TSC2 TSC1 MTOR
27 11.32 TSC2 TSC1 PDGFRA NF2 NF1 MTOR
28 11.15 TSC2 TSC1 MTOR

GO Terms for Benign Ependymoma

Cellular components related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.55 VIM TTR TSC2 TSC1 PDGFRA NF2
2 protein-containing complex GO:0032991 9.5 TTR TSC1 PDGFRA MTOR MEN1 MDM2
3 intermediate filament cytoskeleton GO:0045111 9.43 VIM NES GFAP
4 TSC1-TSC2 complex GO:0033596 9.16 TSC2 TSC1

Biological processes related to Benign Ependymoma according to GeneCards Suite gene sharing:

(show all 14)
# Name GO ID Score Top Affiliating Genes
1 MAPK cascade GO:0000165 9.84 PDGFRA NF1 MEN1 EGFR
2 extracellular matrix organization GO:0030198 9.8 TTR PDGFRA NF1 GFAP
3 negative regulation of protein kinase activity GO:0006469 9.69 TSC2 NF2 NF1
4 hippocampus development GO:0021766 9.63 TSC1 NF2 DCX
5 negative regulation of cell proliferation GO:0008285 9.63 TSC2 TSC1 NF2 NF1 MEN1 CDKN2B
6 cellular response to amino acid stimulus GO:0071230 9.58 PDGFRA MTOR EGFR
7 wound healing GO:0042060 9.56 PDGFRA NF1 MTOR EGFR
8 positive regulation of stress fiber assembly GO:0051496 9.54 TSC1 NF2 MTOR
9 anoikis GO:0043276 9.52 TSC2 MTOR
10 negative regulation of cell size GO:0045792 9.48 TSC1 MTOR
11 Bergmann glial cell differentiation GO:0060020 9.43 VIM GFAP
12 intermediate filament-based process GO:0045103 9.32 VIM GFAP
13 negative regulation of neuron projection development GO:0010977 9.26 VIM TSC1 MDM2 GFAP
14 brain development GO:0007420 9.1 NF2 NF1 NES MTOR MEN1 DCX

Molecular functions related to Benign Ependymoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 9.17 VIM TTR SYP MTOR MDM2 GFAP

Sources for Benign Ependymoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....